| Literature DB >> 34142053 |
Camila O S Souza1, Natália Ketelut-Carneiro1,2, Cristiane M Milanezi1, Lúcia H Faccioli3, Luiz G Gardinassi4, João S Silva1,5.
Abstract
The recognition of fungi by intracellular NOD-like receptors (NLRs) induces inflammasome assembly and activation. Although the NLRC4 inflammasome has been extensively studied in bacterial infections, its role during fungal infections is unclear. Paracoccidioidomycosis (PCM) is a pathogenic fungal disease caused by Paracoccidioides brasiliensis. Here, we show that NLRC4 confers susceptibility to experimental PCM by regulating NLRP3-dependent cytokine production and thus protective effector mechanisms. Early after infection, NLRC4 suppresses prostaglandin E2 production, and consequently reduces interleukin (IL)-1β release by macrophages and dendritic cells in the lungs. IL-1β is required to control fungal replication via induction of the nitric oxide synthase 2 (NOS2) pathway. At a later stage of the disease, NLRC4 impacts IL-18 release, dampening robust CD8+IFN-γ+ T cell responses and enhancing mortality of mice. These findings demonstrate that NLRC4 promotes disease by regulating the production of inflammatory cytokines and cellular responses that depend on the NLRP3 inflammasome activity.Entities:
Keywords: Immunology; Mycology
Year: 2021 PMID: 34142053 PMCID: PMC8184506 DOI: 10.1016/j.isci.2021.102548
Source DB: PubMed Journal: iScience ISSN: 2589-0042
Figure 1Pathogenic activity of NLRC4 during experimental PCM
C57BL/6 (WT) and Nlrc4 mice were intravenously infected with 1x106 viable Pb18 yeasts
(A) Line plots show the percentage of survival of WT and Nlrc4 mice. Animals were monitored daily for 200 days (n = 5 mice/group). ∗∗p < 0.0028 using log rank test of one experiment.
(B) Scatterplots with bars show the fungal load in the lungs, liver, and spleen of WT and Nlrc4 mice at 30 dpi.
(C) P. brasiliensis was stained in the lungs of mice at 30 dpi using the Grocott method.
(D) Histological sections of lungs from WT and Nlrc4−/− mice at 30 dpi using H&E staining. Bar graphs show the percentage of inflammatory infiltrate.
(E) Lung sections from WT and Nlrc4 mice at 30 dpi using the picrosirius red staining. Bar graphs show the percentage of red area. All photomicrography was analyzed using a light microscope, scale bar: 50 μm (n = 9–10 WT and 9–13 Nlrc4 Pb18-infected mice). Error bars depict mean ± SD. Results represent a pool of three independent experiments. Statistically significant differences were evaluated with unpaired t test (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared with WT in each time point).
Figure 2NLRC4 regulates early IL-1β release after P. brasiliensis infection
WT and Nlrc4 and mice were intravenously infected with 1x106 of viable Pb18 yeasts.
(A) Scatterplots with bars show the fungal load in lung of WT and Nlrc4 mice at 7 dpi. Results represent a pool of three independent experiments.
(B) Scatterplots with bars show the quantification of IL-1β at 7 in the lungs of WT and Nlrc4 mice.
(C) Western blotting analysis detecting IL-1β cleavage (p17) in lung homogenates from WT and Nlrc4 mice at 7 dpi. The intensities of IL-1β protein were quantified using iBright™ CL1500 Imaging System.
(D) IL-1β expression was visualized in the lungs of mice at 7 dpi from both groups using immunohistochemistry (Scale bar: 50 μM – left panel). Each column represents the mean ± SD.
(E) Caspase-1 expression was visualized in the lungs of mice at 7 dpi from both groups using immunohistochemistry (Scale bar: 20 μM – right panel). Each column represents the mean ± SD.
(F) Active caspase-1 (p20) was detected by Western blotting in the lungs from WT and Nlc4 mice at 7 dpi. The intensities of active caspase-1 were quantified using iBright™ CL1500 Imaging System.
(G) Active caspase-8 (p18) was detect by Western blotting in the lungs from WT and Nlc4 mice at 7 dpi. The intensities of active caspase-8 were quantified using iBright™ CL1500 Imaging System.
(H) Stacked bars show the percentage of neutrophils (Ly6G+ CD11b+), monocytes (Ly6G−, Ly6C+ CD11b+), macrophages (CD11b+F4/80+MHC-II+), and dendritic cells (CD11c+CD11b+MHC-II+).
(I) Contour plots show representative flow cytometric data and scatterplots with bars show the absolute numbers of macrophages and dendritic cells gated in CD45+IL-1β+ cells at 7 dpi (n = 5 infected mice per group at 7 dpi).Data represent one of two independent experiments (n = 3–5 infected mice per group at each time point). Data are expressed as mean ± SD. Statistically significant differences were evaluated with ANOVA followed by Bonferroni's multiple comparisons test or unpaired t-test (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
See also Figure S1.
Figure 3NLRC4 inhibits IL-1β and NO release by BMDMs incubated with P. brasiliensis
(A and B) BMDMs (2x105 for ELISA and Griess assay or 2x106 for Western blotting) from WT, Nlrc4 and Nlrp3 mice were incubated at MOI 5 for 48 h. (A) Supernatants were used to quantify levels of IL-1β by ELISA. (B) Active form of IL-1β (p17) was determined by Western blotting. WT BMDMs primed with LPS (500ng/mL) and nigericin (20uM) were used as a positive control for the secretion of p17 subunit. The intensities of IL-1β protein were quantified using ImageJ software.
(C) TNF-α was quantified in cell supernatants after 48 hr
(D) BMDMs (2.5x105) from WT and Nlrc4 mice were pretreated with rIFN-γ (50 ng/mL) overnight, followed by Pb18 incubation at MOI 25:1. After 48 h of incubation, BMDMs were washed, lysed, and plated in BHI for quantification of fungal growth.
(E) Fungal load in WT and Nlrc4 BMDMs stimulated with rIL-1β (20ng/mL) or αIL-1β (20ng/mL) overnight.
(F) Supernatants of BMDMs from WT and Nlrc4 cultured with rIFN-γ (50 ng/mL) were collected to measure the levels of nitrite by Griess method.
(G) Supernatants of WT or Nlrc4 BMDMs cultured with rIL-1β (20ng/mL) or αIL-1β (20ng/mL) were collected to measure the levels of nitrite by Griess assay.
(H) Fungal growth was quantified in WT and Nlrc4 BMDMs infected with P. brasiliensis (MOI 25:1) and cultured or not with aminoguanidine (Ag. 1mM) overnight. Data represent one of two independent experiments using triplicates. Results are expressed as mean ± SD. Statistically significant differences were evaluated with ANOVA followed by Bonferroni's multiple comparisons test (#) p < 0.05 compared to Nlrc4 BMDMs not treated with αIL-1β. (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
See also Figure S2.
Figure 4NLRC4-dependent PGE2 suppression promotes P. brasiliensis replication
WT and Nlrc4 mice were intravenously infected with 1x106 of viable Pb18 yeasts and the lungs were collected at 7, 15, and 30 dpi.
(A) Line plots show the kinetics of Nlrp3 expression in WT and Nlrc4 mice before and during 30 days of infection with Pb18.
(B) Line plots show the kinetics of Ptgs2 (cyclooxygenase-2) expression in the lungs along the course of Pb18 infection. Data represent one of two independent experiments performed with triplicates.
(C) Line plots show PGE2 quantification by LC-MS/MS in the lungs of mice of both groups at 7 dpi.
(D) Schematic representation of the treatment with indomethacin.
(E) Scatterplots with bars show the quantification of PGE2 by LC-MS/MS at 7 dpi.
(F) Scatterplots with bars show the quantification of IL-1β by ELISA at 7 dpi.
(G) CFU counting in the lungs from WT and Nlrc4 mice treated or not with indomethacin (2mg/kg) after 30 days of infection with 1x106 Pb18 yeasts. Data represent one independent experiment (n= 3–4 WT or Nlrc4 control mice and n = 3-5 Nlrc4 indomethacin-treated mice per group and time point). Data are expressed as mean ± SD. Statistically significant differences were evaluated with ANOVA followed by Bonferroni's multiple comparisons test (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
See also Figure S3.
Figure 5NLRC4 deficiency promotes robust CD8+ T cell responses during PCM
WT and Nlrc4 mice were intravenously infected with 1x106 viable Pb18 yeasts.
(A) Scatterplot with bars show the quantification of IL-12p40 and IL18 at 30 dpi.
(B) Scatterplot with bars show the quantification of IFN-γ and IL-10 in lungs at 30 dpi.
(C) Contour plots represent flow cytometry data of CD4+IFN-γ+ T cells and scatterplots with bars show the percentage and absolute number of CD4+IFN-γ+ T cells.
(D) Contour plots represent flow cytometry data of CD8+IFN-γ+ T cells and scatterplots with bars show the percentage and absolute number of CD8+IFN-γ+ T cells. Results represent a pool of three independent experiment (n = 11–14 infected mice WT or Nlrc4).
(E) Scatterplots with bars show the absolute number of CD8+perforin+; CD8+granzyme-B+, and CD8+granzyme-A+ T cells. Data represent one independent experiment (n= 4-6 WT or Nlrc4 mice per group). Error bars depict mean ± SD. Statistically significant differences were evaluated with unpaired t test (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
See also Figures S4 and S5.
Figure 6NLRC4 acts as a negative regulator of NLRP3 and affects protective Th1 responses in late stage of P. brasiliensis infection
WT and Nlrc4 mice were intravenously infected with 1x106 of viable Pb18 yeasts and the lungs were collected at 30 dpi.
(A) Schematic representation of the treatment with MCC950 (intranasal 1mg/kg).
(B) Scatterplots with bars show the CFU counting in lungs from WT and Nlrc4 mice treated or not with MCC950 (1 mg/kg) after 30 days of infection with 1x106 Pb18 yeasts.
(C and D) Scatterplots with bars show the quantification of IL-18 (C) and IFN-γ (D) by ELISA in the lungs at 30dpi.
(E) Contour plots represent flow cytometry data of CD8+IFN-γ+ T cells and scatterplots with bars show the percentage of CD8+IFN-γ+ T cells in the lungs. Data represent one independent experiment (n= 4-6 WT or Nlrc4 control mice and n = 4 Nlrc4 MCC950-treated mice per group). Data are expressed as mean ± SD. Statistically significant differences were evaluated with ANOVA followed by Bonferroni's multiple comparisons test (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| FITC anti-mouse CD3ε (clone: 145-2C11) | BioLegend | Cat#100306; RRID: |
| Pacific BlueTM anti-mouse CD4 (clone: RM4-4) | BioLegend | Cat#116008; RRID: |
| PE-Cy7TM or PerCP anti-mouse CD8a (clone: 53-6.7) | BD Bioscience | Cat#552877; RRID: |
| Pacific BlueTM anti-mouse CD45 (clone: 30-F11) | BioLegend | Cat#103126; RRID: |
| PE anti-human/mouse CD11b (clone: M1/70) | BioLegend | Cat#101208; RRID: |
| PE/Cyanine7 anti-mouse CD11c (clone: N418) | BioLegend | Cat#117318; RRID: |
| FITC anti-mouse I-A/I-E (clone: M5/114.5.2) | BD Bioscience | Cat#553623; RRID: |
| PerCP anti-mouse Ly6C (clone: HK1.4) | BioLegend | Cat#128028; RRID: |
| Alexa Fluor® 488 anti-mouse Ly6G (clone:1A8) | BioLegend | Cat#127626; RRID: |
| APC anti-mouse IFN-γ (clone: XM 61.2) | BioLegend | Cat#505810; RRID: |
| APC anti-human/mouse IL-1β (pro-form) (clone: NJTEN3) | eBioscience | Cat#17-7114-80; RRID: |
| PE anti-mouse Perforin (clone: eBioOMAK-D) | eBioscience | Cat#12-9392-82; RRID: |
| Alexa Flour® 647 anti-human/mouse Granzyme B (clone:GB11) | BioLegend | Cat#515405; RRID: |
| PE anti-mouse Granzyme A (clone: 3G8.5) | BioLegend | Cat#149704; RRID: |
| Rabbit polyclonal to IL-1β | Abcam | Cat#ab9722; RRID: |
| Goat polyclonal anti-Caspase-1 p20 | Santa Cruz Biotechnology | Cat#sc-1597; RRID:A |
| Rabbit polyclonal NOS2 | Santa Cruz Biotechnology | Cat#sc-650; RRID: |
| Rat monoclonal anti-Caspase-1 p20 | Genentech | Clone:4B4 |
| Goat polyclonal anti-IL-1β | Sigma-Aldrich | Cat#I3767-1MG; RRID: |
| Rabbit mAb cleaved Caspase-8 (Asp387) (D5B2) XP® | Cell Signaling Technology | Cat#8592S; RRID: |
| Rabbit polyclonal anti-beta Actin | Abcam | Cat#ab8227; RRID: |
| BioXCell | Cat#BE0246; RRID: | |
| Recombinant mouse IFN-γ | Biolegend | Cat#575304 |
| Recombinant mouse IL-1β/IL-1F2 Protein | R&D Systems | Cat#401-ML |
| MCC950 | InvivoGen | Cat#inh-mcc |
| Aminoguanidine hydrochloride | Sigma-Aldrich | Cat#19371-19-5 |
| PGE2 | Cayman Chemical | Cat#14010 |
| CAY10526 | Cayman Chemical | Cat#10010088 |
| Indomethacin | Sigma-Aldrich | Cat#I8280 |
| Nigericin sodium salt | Sigma-Aldrich | Cat#N7143 |
| LPS-EK Ultrapure | InvivoGen | Cat#tlrl-peklps |
| PMA | Abcam | Cat#ab120297 |
| Ionomicina | Sigma-Aldrich | Cat#I0634 |
| Brefeldin A | BioLegend | Cat#420601 |
| Deoxyribonuclease I from bovine pancreas | Sigma-Aldrich | Cat#DN25 |
| Collagenase from | Sigma-Aldrich | Cat#C5138 |
| Mouse IL-1β ELISA MAXTM Standard Set | BioLegend | Cat#432601 |
| Mouse TNF-α DuoSet ELISA | R&D Systems | Cat#DY410 |
| Mouse IL-12/IL-23 (p40) ELISA MAXTM Standard Set | BioLegend | Cat#431603 |
| Mouse IL-18 ELISA Kit | MBL | Cat#7625 |
| Mouse IFN-γ ELISA MAXTM Standard Set | BioLegend | Cat#430801 |
| Mouse IL-10 ELISA MAXTM Standard Set | BioLegend | Cat#431411 |
| Mouse IL-1ra/IL-1F3 DuoSet ELISA | R&D Systems | Cat#DY480 |
| Mouse IL-17 DuoSet ELISA | R&D Systems | Cat#DY421 |
| Mouse IL-6 DuoSet ELISA | R&D Systems | Cat#DY406 |
| Mouse CXCL1/KC DuoSet ELISA | R&D Systems | Cat#DY453 |
| Mouse CXCL2/MIP-2 DuoSet ELISA | R&D Systems | Cat#DY452 |
| PierceTM Coomassie (Bradford) Protein Assay | Thermo Fisher Scientific | Cat#23200 |
| L-929 | ATCC | ATCC CCL-1 |
| C57BL/6J mice | Jackson Laboratory | 000664 |
| NLRP3 knockout mice | N/A | |
| NLRC4 knockout mice | N/A | |
| ASC knockout mice | N/A | |
| NLRC4 and ASC double-knockout mice ( | This paper | N/A |
| N/A | ||
| Mouse | 5’ – CAC CCC CAC TGA GAC TGA TAC ATA – 3’ | |
| Mouse | 3’- TCA CAT GTC TCG ATC CCA GTA GA-5’ | |
| Mouse | This article | 5’ – GCA GCG CAT CGC CTT CTA TC– 3’ |
| Mouse | This article | 3’-CGG TGG TTG CTA GGA GAT GG-5’ |
| Mouse | This article | 5’ – GTG GAA AAA CCT CGT CCA GA– 3’ |
| Mouse | This article | 3’- GCT CGG CTT CCA GTA TTG AG-5’ |
| Mouse | 5’ CGA AAC GCT TCA CTT CCA A 3’ | |
| Mouse | 3’ – TGA GCC TAT ATT GCT GTG GCT-5’ | |
| Image J (v1.51) | ||
| GraphPad Prism 8.0 | GraphPad Software | |
| FlowJo software (v10.0.7) | Tree Star, Inc, Ashland, OR, USA | |
| FACSDiva software (v8.0.1) | BD Biosciences | |
| iBrightTM CL1500 Imaging System | Thermo Fisher Scientific | Cat#A44114 |
| BD FACS CANTOTM II Cell Analyzer | BD Bioscience | |
| TriploTOF® 5600+System | Sciex | |